The Effect of Mesenchymal Stromal Cells on the Mortality of Patients with Sepsis and Septic Shock: A Promising Therapy

Emine Alp, Zeynep Burcin Gonen, Kursat Gundogan, Aliye Esmaoglu, Leylagul Kaynar, Aysun Cetin, Musa Karakukcu, Mustafa Cetin, Gamze Kalin, Mehmet Doganay, Emine Alp, Zeynep Burcin Gonen, Kursat Gundogan, Aliye Esmaoglu, Leylagul Kaynar, Aysun Cetin, Musa Karakukcu, Mustafa Cetin, Gamze Kalin, Mehmet Doganay

Abstract

Purpose: Sepsis and septic shock are the major causes of death in intensive care units. This study aimed to evaluate the clinical safety and efficacy of mesenchymal stem cells (MSCs) in sepsis and septic shock patients.

Methods: Ten patients were enrolled in the study. Adipose-derived MSC infusions were given (1 × 106/kg, on the 1st, 3rd, 5th, 7th, and 9th days of therapy) together with standard therapy. Before the MSC applications, blood samples were collected for cytokine assessment (TNF-α, IFN-γ, IL-2, IL-4, IL-6, IL-10). The clinical and laboratory improvements were recorded and compared with control groups selected retrospectively. The clinical trial was registered on 16.03.2022 with the registration number NCT05283317.

Results: In the study group, the ages of patients ranged from 22 to 68 years, and APACHE II scores ranged from 14 to 42. In the control group, ages ranged from 22 to 80 years and their APACHE II scores were between 14-35. The survival rate in the study group was 100% on the 14th day whereas it was 70% on the 28th day. A significant decrease in the SOFA score (adjusted), clinical, and laboratory improvements were observed during the MSC administration. However, no significant cytokine level changes were observed. In the control group, the survival rate of 20 patients was 70% on the 14th day, whereas 60% was on the 28th day. While deaths were observed in the control group in the first week of treatment, deaths in the MSCs group were observed between the 15th and 28th days.

Conclusion: MSCs treatment may have a positive impact on the survival rates of sepsis during the early phase. However, further randomized controlled studies with a large group of patients are needed. Trial Registration. This trial is registered with ClinicalTrials.gov Identifier: NCT05283317.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Copyright © 2022 Emine Alp et al.

Figures

Figure 1
Figure 1
Histogram of the ADMSCs (a) and the mean expression levels of the markers (b).

References

    1. Singer M., Deutschman C. S., Seymour C. W., et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3) JAMA . 2016;315(8):801–810. doi: 10.1001/jama.2016.0287.
    1. Martin-Loeches I., Levy M., Artigas A. Management of severe sepsis: advances, challenges, and current status. Drug Design, Development and Therapy . 2015;9:2079–2088. doi: 10.2147/dddt.s78757.
    1. Keane C., Jerkic M., Laffey J. G. Stem cell-based therapies for sepsis. Anesthesiology . 2017;127(6):1017–1034. doi: 10.1097/aln.0000000000001882.
    1. Tupchong K., Koyfman A., Foran M. Sepsis, severe sepsis, and septic shock: a review of the literature. African Journal of Emergency Medicine . 2015;5(3):127–135. doi: 10.1016/j.afjem.2014.05.004.
    1. Munford R. S. Severe sepsis and septic shock: the role of gram-negative bacteremia. Annual Review of Pathology: Mechanisms of Disease . 2006;1(1):467–496. doi: 10.1146/annurev.pathol.1.110304.100200.
    1. Esel D., Doganay M., Alp E., Sumerkan B. Prospective evaluation of blood cultures in a Turkish university hospital: epidemiology, microbiology and patient outcome. Clinical Microbiology and Infections . 2003;9(10):1038–1044. doi: 10.1046/j.1469-0691.2003.00714.x.
    1. Harris R. L., Musher D. M., Bloom K., et al. Manifestations of sepsis. Archives of Internal Medicine . 1987;147(11):1895–1906. doi: 10.1001/archinte.1987.00370110023003.
    1. Fourrier F., Chopin C., Goudemand J., et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Chest . 1992;101(3):816–823. doi: 10.1378/chest.101.3.816.
    1. Aygen B., Inan M., Doğanay M., Keleştimur F. Adrenal functions in patients with sepsis. Experimental and Clinical Endocrinology & Diabetes: Official Journal, German Society of Endocrinology [and] German Diabetes Association . 1997;105(3):182–186. doi: 10.1055/s-0029-1211749.
    1. Mayer J., Hajek R., Vorlicek J., Tomiska M. Sepsis and septic shock. Supportive Care in Cancer . 1995;3(2):111–119. doi: 10.1007/bf00365850.
    1. Saeedi P., Halabian R., Fooladi A. A. I. Mesenchymal stem cells preconditioned by staphylococcal enterotoxin B enhance survival and bacterial clearance in murine sepsis model. Cytotherapy . 2019;21(1):41–53. doi: 10.1016/j.jcyt.2018.11.002.
    1. Castro-Manrreza M. E., Montesinos J. J. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. Journal of Immunology Research . 2015;2015:20. doi: 10.1155/2015/394917.394917
    1. Mei S. H. J., Haitsma J. J., Dos Santos C. C., et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. American Journal of Respiratory and Critical Care Medicine . 2010;182(8):1047–1057. doi: 10.1164/rccm.201001-0010oc.
    1. Weil B. R., Markel T. A., Herrmann J. L., Abarbanell A. M., Kelly M. L., Meldrum D. R. Stem cells in sepsis. Annals of Surgery . 2009;250(1):19–27. doi: 10.1097/sla.0b013e3181a77b9c.
    1. McIntyre L. A., Stewart D. J., Mei S. H. J., et al. Canadian critical care trials group the Canadian critical care translational biology group. Cellular immunotherapy for septic shock. A phase I clinical trial. American Journal of Respiratory and Critical Care Medicine . 2018;197(3):337–347.
    1. C.T..gov Identifier NCT03158727.
    1. C.T..gov Identifier NCT02883803.
    1. C.T..gov Identifier NCT03369275.
    1. Galstian G. M., Parovichnikova E. N., Makarova P. M., et al. The results of the Russian clinical trial of mesenchymal stromal cells (MSCs) in severe neutropenic patients (pts) with septic shock (SS) (RUMCESS trial) Blood . 2015;126(23):p. 2220. doi: 10.1182/blood.v126.23.2220.2220.
    1. C.T..gov Identifier: NCT05283317.
    1. Schlosser K., Wang J.-P., Dos Santos C., et al. Effects of mesenchymal stem cell treatment on systemic cytokine levels in a phase 1 dose escalation safety trial of septic shock patients∗. Critical Care Medicine . 2019;47(7):918–925. doi: 10.1097/ccm.0000000000003657.
    1. He X., Ai S., Guo W., et al. Umbilical cord-derived mesenchymal stem (stromal) cells for treatment of severe sepsis: aphase 1 clinical trial. Translational Research . 2018;199:52–61. doi: 10.1016/j.trsl.2018.04.006.
    1. Pedrazza L., Lunardelli A., Luft C., et al. Mesenchymal stem cells decrease splenocytes apoptosis in a sepsis experimental model. Inflammation Research . 2014;63(9):719–728. doi: 10.1007/s00011-014-0745-1.
    1. Xu J., Woods C. R., Mora A. L., et al. Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology . 2007;293(1):L131–L141. doi: 10.1152/ajplung.00431.2006.
    1. Wannemuehler T. J., Manukyan M. C., Brewster B. D., et al. Advances in mesenchymal stem cell research in sepsis. Journal of Surgical Research . 2012;173(1):113–126. doi: 10.1016/j.jss.2011.09.053.
    1. Jawad I., Lukšić I., Rafnsson S. B. Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality. Journal of global health . 2012;2(1) doi: 10.7189/jogh.02.010404.010404
    1. Kebriaei P., Robinson S. Mesenchymal stem cell therapy in the treatment of acute and chronic graft versus host disease. Frontiers in Oncology . 2011;1:p. 16. doi: 10.3389/fonc.2011.00016.
    1. Moemen M. E. Prognostic categorization of intensive care septic patients. World Journal of Critical Care Medicine . 2012;1(3):67–79. doi: 10.5492/wjccm.v1.i3.67.
    1. Abraham E., Laterre P.-F., Garg R., et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. New England Journal of Medicine . 2005;353(13):1332–1341. doi: 10.1056/nejmoa050935.
    1. Ranieri V. M., Thompson B. T., Barie P. S., et al. Drotrecogin alfa (activated) in adults with septic shock. New England Journal of Medicine . 2012;366(22):2055–2064. doi: 10.1056/nejmoa1202290.
    1. Santamaria P. Cytokines and chemokines in autoimmune disease: an overview. Advances in Experimental Medicine and Biology . 2003;520:1–7. doi: 10.1007/978-1-4615-0171-8_1.
    1. Ferrari G., Cusella-De Angelis G., Coletta M., et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science . 1998;279(5356):1528–1530. doi: 10.1126/science.279.5356.1528.
    1. Yang J., Jia Z. Cell-based therapy in lung regenerative medicine. Regenerative Medicine Research . 2014;2(1):p. 7. doi: 10.1186/2050-490x-2-7.
    1. Noiseux N., Marquis-Gravel G., Mansour S., Shahzad U., Stewart D. J., Yau T. M. The current state of stem cell therapeutics: Canadian approaches in the international context. Canadian Journal of Cardiology . 2014;30(11):1361–1369. doi: 10.1016/j.cjca.2014.04.031.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться